Key Highlights
- Eli Lilly has committed to purchasing Centessa Pharmaceuticals at $38 per share cash, representing approximately $6.3 billion in total value
- An additional contingent value right (CVR) payment of roughly $9 per share could elevate the transaction to $7.8 billion
- Shares of Centessa traded in the U.S. skyrocketed 46% during premarket hours
- The transaction focuses on obtaining Centessa’s sleep-wake disorder treatment portfolio
- Separately, Lilly unveiled a $2.75 billion partnership with Insilico Medicine focused on AI-driven drug development
Eli Lilly revealed on Tuesday its intention to purchase Centessa Pharmaceuticals in a transaction worth approximately $6.3 billion. The pharmaceutical giant is offering $38 cash per share for the Frankfurt-based biotechnology company.
Additionally, Lilly is providing one non-transferrable contingent value right valued at approximately $9 per share. Should this CVR materialize, the aggregate transaction value would climb to about $7.8 billion.
Shares of Centessa trading on U.S. exchanges experienced a dramatic 46% spike in premarket activity after the disclosure. This substantial increase demonstrates the significant premium Lilly is willing to pay to secure Centessa’s sleep medication assets.
Centessa Pharmaceuticals plc, CNTA
The transaction centers on sleep-wake disorder therapies, representing a new therapeutic area for Lilly. Centessa possesses a specialized development portfolio that Lilly anticipates can achieve commercial success.
This represents Lilly’s second significant transaction announcement within consecutive days. The previous day, the pharmaceutical company revealed a $2.75 billion collaboration with Insilico Medicine to commercialize AI-generated therapeutics worldwide.
The Insilico partnership, which leverages artificial intelligence for drug candidate identification, demonstrates Lilly’s strategy of combining conventional pharmaceutical development with cutting-edge technology platforms.
Strategic Entry Into Sleep Disorder Market
The Centessa transaction represents a deliberate strategic expansion into sleep-wake disorder therapeutics. This therapeutic category has garnered increasing interest from leading pharmaceutical companies in recent years.
Centessa has been advancing orexin receptor agonists, compounds that stimulate the brain’s wakefulness pathways. These molecules show considerable promise for addressing conditions including narcolepsy and chronic daytime drowsiness.
Lilly’s decision to offer a substantial premium indicates strong conviction in the pipeline’s clinical promise. The CVR mechanism also ensures that portions of the compensation depend on achieving specific future development objectives.
Artificial Intelligence Partnership Caps Eventful Week
The Insilico collaboration, disclosed Monday, contributes another strategic component to Lilly’s recent initiatives. Insilico employs artificial intelligence to engineer novel drug candidates, an approach that may significantly reduce early-phase development timelines.
Lilly stated it will obtain licenses and advance therapeutics identified through Insilico’s technology platform. Complete financial terms extending beyond the $2.75 billion announced figure remain undisclosed.
Announcing two transactions of this magnitude within a 24-hour period is uncommon even for an organization of Lilly’s stature. LLY shares were trading approximately 1% higher Tuesday morning as market participants evaluated both agreements.
Centessa’s Frankfurt-traded securities also experienced significant upward movement following the news, reflecting the cash proposal substantially exceeding its recent market valuation.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
